US EditionBioNTech to Buy CureVac in $1.25B Stock Deal That Would Also End mRNA Patent Dispute
- BioNTech announced on June 11, 2025, its plan to acquire CureVac in a $1.25 billion all-stock deal to unite their mRNA cancer treatment efforts.
- The acquisition follows years of patent litigation between the firms and aims to circumvent costly royalty risks related to Comirnaty mRNA patents.
- Both companies expect the integration will combine complementary mRNA technologies and manufacturing to advance innovative cancer immunotherapies over the coming years.
- BioNTech CEO Ugur Sahin described the deal as a key step forward in the company’s focus on cancer treatment and a commitment to advancing the development of future therapies in oncology.
- Both companies’ boards have unanimously approved the transaction, which is anticipated to finalize in 2025 and aligns with BioNTech’s ambition to develop innovative treatment benchmarks across multiple cancer types.
72 Articles
72 Articles
BioNTech to Buy CureVac in $1.25B Stock Deal That Would Also End mRNA Patent Dispute
BioNTech is acquiring CureVac in a deal that brings messenger RNA manufacturing capability and cancer immunotherapy candidates. Analysts say the M&A deal is a way to essentially settle out of court the ongoing mRNA patent dispute between the companies following some recent CureVac legal wins. The post BioNTech to Buy CureVac in $1.25B Stock Deal That Would Also End mRNA Patent Dispute appeared first on MedCity News.
The German company Biontech, which has become world famous with a Corona vaccine, wants to buy its competitors in Tübingen. The bundling of the forces is to create a biotech champion.
derwesten.de
Stock hammers around Biontech and Curevac! There is a spectacular takeover in billions.
Once they were both considered to be large biotech hope carriers, they delivered a head-to-head race at the Corona vaccine, arguing for patents. Now Biontech from Mainz is reaching for Curevac from Tübingen.
Once they were both considered to be large biotech hope carriers, they delivered a head-to-head race at the Corona vaccine, arguing for patents. Now Biontech from Mainz is reaching for Curevac from Tübingen.
Coverage Details
Bias Distribution
- 52% of the sources are Center
To view factuality data please Upgrade to Premium
